Hormonal contraceptive regimens in the perimenopause

被引:14
作者
Hardman, Sarah M. R. [1 ]
Gebbie, Ailsa E. [1 ]
机构
[1] NHS Lothian Family Planning & Well Woman Serv, Edinburgh, Midlothian, Scotland
关键词
Hormonal; Contraceptive; Regimens; Perimenopause; BONE-MINERAL DENSITY; DEPOT-MEDROXYPROGESTERONE ACETATE; LONG-TERM USE; COMBINED ORAL-CONTRACEPTIVES; 1-YEAR FOLLOW-UP; INTRAUTERINE SYSTEM; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; OVULATION INHIBITION; BLEEDING PATTERNS;
D O I
10.1016/j.maturitas.2009.05.001
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
030301 [社会学]; 100201 [内科学];
摘要
Perimenopausal women have low fertility but still need contraception if they are sexually active. They often have co-existing menstrual problems and menopausal symptoms. No method of contraception is contraindicated by age alone. In addition to highly effective contraception, hormonal methods offer non-contraceptive benefits which can improve quality of life for perimenopausal women. Combined hormonal oral contraception has been available for many decades. The combined vaginal ring and transdermal patch are newer methods offering alternative delivery systems but similar risk profiles to oral preparations. New combinations containing naturally occurring estrogens in place of the synthetic hormone ethinylestradiol are now available and, in theory, could be safer. The progestogen-only methods have an excellent safety profile and have a range of delivery systems and dosages to suit all. Concerns regarding loss of bone mineral density with the injectable depot medroxyprogesterone acetate continue but to date there is no evidence that this translates into higher fracture risk. Effective use of any method of contraception is strongly dependent on good counselling and support from healthcare professionals. Risks should be explained in absolute terms for each individual woman, enabling her to make an informed choice on evidence-based medicine and not influenced by ill-informed media publicity. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 106 条
[1]
Cardiovascular risk factors and venous thromboembolism - A meta-analysis [J].
Ageno, Walter ;
Becattini, Cecilia ;
Brighton, Timothy ;
Selby, Rita ;
Kamphuisen, Pieter W. .
CIRCULATION, 2008, 117 (01) :93-102
[2]
Akerlund M, 1997, ACTA OBSTET GYN SCAN, V76, P63
[3]
LEVONORGESTREL-RELEASING INTRAUTERINE-DEVICE IN THE TREATMENT OF MENORRHAGIA [J].
ANDERSSON, JK ;
RYBO, G .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1990, 97 (08) :690-694
[4]
Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5
[5]
ARCHER DF, 2008, AM J OBSTET GYNECOL
[6]
Change in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg [J].
Arias, Raquel D. ;
Jain, John K. ;
Brucker, Cosima ;
Ross, Doug ;
Ray, Amrit .
CONTRACEPTION, 2006, 74 (03) :234-238
[7]
Use of the levonorgestrel-releasing intrauterine system and breast cancer [J].
Backman, T ;
Rauramo, I ;
Jaakkola, K ;
Inki, P ;
Vaahtera, K ;
Launonen, A ;
Koskenvuo, M .
OBSTETRICS AND GYNECOLOGY, 2005, 106 (04) :813-817
[8]
Bone mineral density during long-term use of the progestagen contraceptive implant Implanon® compared to a non-hormonal method of contraception [J].
Beerthuizen, R ;
van Beek, A ;
Massai, R ;
Mäkäräinen, L ;
in't Hout, J ;
Bennink, HC .
HUMAN REPRODUCTION, 2000, 15 (01) :118-122
[9]
Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception [J].
Beksinska, ME ;
Smit, JA ;
Kleinschmidt, I ;
Farley, TMM ;
Mbatha, F .
CONTRACEPTION, 2005, 71 (03) :170-175
[10]
Ovulation inhibition by estetrol in an in vivo model [J].
Bennink, Herian J. T. Coelingh ;
Skouby, Sven ;
Bouchard, Philippe ;
Holinka, Christian F. .
CONTRACEPTION, 2008, 77 (03) :186-190